BioCryst Pharmaceuticals Inc., of Birmingham, Ala., presented data that confirmed clinical activity of its drug forodesine in chronic lymphocytic leukemia...ChemGenex Pharmaceuticals Ltd., of Melbourne, Australia, presented updated clinical data showing that Omapro (omacetaxine mepesuccinate) produced durable hematologic and cytogenetic responses in a significant proportion of chronic phase chronic myeloid leukemia (CML) patients who had failed previous attempts to control their disease with two or

Anthera said there have been no reports of patient-related side effects or problems with drug administration that could be attributed to the problem to date, and no serious adverse events have been reported to the company in the PEARL-SC trial...An additional study also demonstrated the bioequivalence of the Gen2 device and the clinical inhaler...Tengion Inc., of East Norriton, Pa., said the first implanted bladder patient in its ongoing trial completed the one-month, postoperative clinical assessment

Results were published in the Journal of Clinical Oncology...In 60 patients with a two-year history of persistent allergic rhinitis and positive skin allergen test, treatment with WF10 resulted in a significant change in Total Nasal Symptom Score without significant adverse events

The trial will be carried out in cooperation with the NCIC Clinical Trials Group in Canada and will test single agent activity of AT9283...Overall, the safety of DB959 was comparable to placebo with no reports of moderate, severe or serious adverse events in any subjects

The treatment was well tolerated, while adverse events were mild to moderate in severity and predominantly local reactions at the application site, with all adverse events resolved after the end of treatment

Phase I data have shown substantial clinical activity and good tolerability among nearly 30 patients...The drug was well-tolerated with only 1.6 percent of patients reporting triptan-related adverse events

Access Pharmaceuticals Inc., of Dallas, reported clinical findings showing that MuGard, its mucoadhesive wound liquid, provided a significant improvement and/or stabilization of oral mucositis lesions and symptoms of oral mucositis in more than 75 percent of cancer patients treated with radiotherapy/chemotherapy...Adverse events were balanced in both groups, and cases of osteonecrosis of the jaw occurred in 1.8 percent of denosumab patients and in 1.3 percent of Zometa patients

The study was published online ahead of print in the Journal of Clinical Oncology with an accompanying editorial...The safety data showed the drug to be well tolerated, with adverse events consistent with those observed with other antihistamine nasal sprays and generally rated as mild

The compound also was found to be safe, with no serious adverse events...Santarus Inc., of San Diego, said an integrated analysis of two trials of Rhucin (recombinant human C1 inhibitor), published in the October 2010 issue of the Journal of Allergy and Clinical Immunology, showed that Rhucin significantly reduced the time to beginning of relief of symptoms for all anatomical locations studied at both dosage strengths compared to placebo in patients with hereditary angioedema

Results also demonstrated statistically significant improvements in clinical symptom scores and reductions in the incidence of bronchiolitis obliterans syndrome...The primary adverse event associated with CBLB502 administration was a transient flu-like syndrome consistent with what was observed in the previous trial and which generally resolved within 24 hours

Adverse events were uncommon, and there were no serious ocular or systemic adverse events

Clinical Data Inc., of Newton, Mass., reported Phase I data showing that Stedivaze (apadenoson), a selective agonist of the adenosine A2A receptor subtype, demonstrated overall safety and tolerability in patients with asthma and chronic obstructive pulmonary disease (COPD...Data from the COPD study also showed no effects on pulmonary function, and there appeared to be no association between severity of disease and the overall incidence or severity of treatment- emergent adverse events

10, 2010, issue of the Journal of Clinical Oncology...In the treatment group, 68 percent of patients reported adverse events vs. 50 percent in the control group

Chimerix Inc., of Durham, N.C., said it presented promising clinical data for CMX001 in a late-breaker poster session at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy...ViroPharma Inc., of Exton, Pa., presented Phase I data showing that VP20621 was well tolerated with no serious adverse events and no discontinuations due to adverse events

An independent safety review board reviewed all of the safety data from the clinical trial and preliminary results demonstrated that Bendavia appears to be safe and well tolerated at the doses evaluated, with no serious adverse events reported...The initial clinical indication for Bendavia is the treatment of ischemia reperfusion injury, a common complication of interventional procedures for acute myocardial infarction

Nine of the discontinuations were due to adverse events...Preliminary data showed that the drug was well tolerated at all dose levels, with no drug-related serious adverse events or dose-related trends in frequency or type of adverse events

The first two cohorts of the clinical study have been successfully completed without serious adverse events

No adverse events associated with ADXS11-001 administration were observed in any patient...Intellect is the sponsor of this trial, which was conducted by Kendle, a global clinical research organization, through the Kendle Clinical Pharmacology Unit located in Utrecht, the Netherlands

Data from the pilot study showed no significant adverse events and documented a clear trend for temporary reduction in smell perception that spontaneously reversed over time...The drug also was generally well tolerated, and all adverse events were mild except for one incidence of pharyngitis of moderate severity